Portland, OR -- (SBWIRE) -- 09/07/2017 -- The major factors that contribute to the growth of the Vasculitis Treatment Market include increasing prevalence of chronic diseases due to sedentary lifestyles, rise in geriatric population who are more prone to cardiovascular diseases, high demand for minimally invasive procedures, better healthcare infrastructure, and technological advancements & innovations that lead to intense competition among key players. However, lack of trained professionals and stringent governmental regulations for these drugs restrict the market growth. Recent innovations, which embed the introduction of innovative ideas such as use of sequential magnetic resonance imagingmagnetic resonance angiography (MRIMRA) will provide better results to the physicians and allow them to work more efficiently, thus fostering the market growth.

The global vasculitis treatment market is segmented on the basis of drug class, disease type, end user, and region. Based on drug class, it is divided into corticosteroids, immunosuppressants, and biologics. Based on disease type, the market is categorized into small vessel and medium vessel vasculitis. According to end user, the market is divided into government, hospitals, medical clinics, and others. Geographically, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Get PDF Brochure of this report: https://www.alliedmarketresearch.com/request-toc-and-sample/3523

The key players that operate in this market include GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Celgene Corporation, Ablynx, Gilead, Novartis AG, Bristol-Myers Squibb Company, Novo Nordisk A/S, Eli Lilly and Company, and Merck & Co., Inc.

Vasculitis Treatment Market Key Segments:

By Drug Class

- Corticosteroids
- Immunosuppressants
- Biologics

By Disease Type

- Small Vessel Vasculitis
- Medium Vessel Vasculitis

By End User

- Government
- Hospitals
- Medical Clinics
- Others

Early buyers will receive 20% customization on this report